Rutgers: Triple Therapy Halved the Risk of Death Among Patients Hospitalized With Severe COVID-19
August 09, 2022
August 09, 2022
NEW BRUNSWICK, New Jersey, Aug. 9 (TNSres) -- Rutgers University issued the following news:
Hospitalized patients on high-flow oxygen for severe COVID-19 pneumonia were nearly 50 percent less likely to die when baricitinib was added to the antiviral remdesivir and the steroid dexamethasone, according to Rutgers research.
"All three of the medications work in different ways, so it makes sense that you'd get added therapeutic benefit by combining them," sai . . .
Hospitalized patients on high-flow oxygen for severe COVID-19 pneumonia were nearly 50 percent less likely to die when baricitinib was added to the antiviral remdesivir and the steroid dexamethasone, according to Rutgers research.
"All three of the medications work in different ways, so it makes sense that you'd get added therapeutic benefit by combining them," sai . . .